A ortic valve stenosis (AVS) is the most common valvular disease in the Western world. Its prevalence increases with age, reaching 2% to 3% of individuals aged >65 years. 1 The burden of AVS is high and is expected to double within the next 50 years. 2 To date, the only effective treatment for AVS is aortic valve replacement, for which costs have been estimated to be up to $120 000. 3 The identification of risk factors for AVS is likely to help the medical and scientific communities develop novel and innovative treatment strategies. Up to now, male sex, smoking, hypertension, dyslipidemia, metabolic syndrome, and impaired glucose-insulin homeostasis have been associated with AVS incidence or progression. 4,5
that plasma levels of lipoprotein(a) were ≈1.5-fold higher in 101 patients with AVS compared with matched controls, although this relationship did not reach statistical significance. Investigators of the Cardiovascular Health Study have shown that patients with either aortic valve sclerosis or AVS had significantly higher lipoprotein(a) levels compared with controls, but this association was documented cross-sectionally at baseline. 5 To date, no prospective study has suggested a role for lipoprotein(a) levels in the pathophysiology of AVS.
The objective of our study was to test the hypothesis that lipoprotein(a) levels are associated with an increased risk of developing AVS in a large population-based study of asymptomatic men and women. We also tested the potential causality of this association by studying a common variant in the LPA gene that is strongly associated with lipoprotein(a) levels. We tested these hypotheses in the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study as well as in a case-control study of AVS.
Methods

EPIC-Norfolk Study
The EPIC-Norfolk prospective population study is a population-based cohort of 25 639 men and women aged between 39 and 79 years residing in Norfolk, United Kingdom. The design and methods of the study have been described in details. 9 Participants were recruited from age-sex registers of general practices in Norfolk as part of the 10-country collaborative EPIC study. The study cohort was closely similar to UK population samples for many characteristics, including anthropometry, blood pressure, and lipids, but with a lower proportion of smokers. At the baseline survey conducted between 1993 and 1997, participants completed a detailed health-and-lifestyle questionnaire. Blood was taken by venipuncture into plain and citrate tubes. Blood samples were processed for various assays at the Department of Clinical Biochemistry, University of Cambridge, or stored at −80°C. Hospitalizations of study participants were identified through the East Norfolk Health Authority database, which records all hospital contacts throughout England and Wales for Norfolk residents. Vital status for all EPIC-Norfolk participants was obtained through death certification at the Office for National Statistics. The underlying cause of death or hospital admission was coded by trained nosologists according to the International Classification of Diseases, 10th Revision. Participants were identified as having incident aortic stenosis if they were hospitalized with AVS (International Classification of Diseases, 10th Revision, code I35) as an underlying cause or if they died with AVS as an underlying cause. The Norwich District Health Authority Ethics Committee approved the study, and all participants gave signed informed consent.
Montreal Heart Institute Biobank
A total of 405 consecutive patients with mild to severe AVS were recruited. AVS was defined by an aortic jet velocity >2.5 m/s. Patients with bicuspid AVS, AVS of rheumatic cause, or patients who underwent aortic valve replacement for any other reason than AVS (aortic insufficiency, infective endocarditis, congenital, etc) were not included. Of these 405 patients, 176 underwent aortic valve replacement surgery. The control group included 415 patients without AVS, with an anatomically normal tricuspid valve and without aortic valve sclerosis or stenosis as documented by echocardiography. All controls were characterized by an aortic jet velocity <1.7 m/s. Cases were excluded if they had undergone radiotherapy because of any type of cancer in the thoracic area (breast, trachea, bronchus, or lung cancer) before the diagnosis of AVS. Other exclusion criteria for both cases and controls included the presence of a bicuspid aortic valve, renal insufficiency defined as serum creatinine level ≥200 μmol/L, hyperparathyroidism, Paget disease of the bone, or lupus erythematosus.
The study protocol was approved by the Montreal Heart Institute (MHI) Research Ethics Board, and all participants gave signed informed consent.
Genotyping and Laboratory Measurements
In EPIC-Norfolk, the SNP was genotyped using Custom TaqMan SNP Genotyping Assays (Applied Biosystems, Warrington, United Kingdom). The genotyping assays were performed using 10 ng of genomic DNA in a 2.5-μL reaction volume on 384-well plates using a G-Storm GS4 Thermal Cycler (GRI, Rayne, United Kingdom). The ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) was used for end point detection and allele calling. The SNP passed the quality control criteria in the EPIC-Norfolk study (call rate, >95%; blind duplicate concordance, ≥95%). In the MHI Biobank, genotyping was performed using both the Infinium HumanExome Beadchip and the Cardio-MetaboChip (Illumina, CA). Those genotyping panels have been described in detail elsewhere. 10, 11 The rs10455872 was genotyped using the Sequenom Mass Array. Genotyping was performed at the Beaulieu-Saucier Université de Montréal Pharmacogenomics Center. Seven duplicate controls genotyped on the Infinium HumanExome Beadchip and 2 duplicates for the Cardio-MetaboChip had concordance rates >0.9998. Quality checks for genotypes were performed to exclude completely failed SNPs, uninformative SNPs, sample and genotyping call rates <98%, and SNPs with plate bias. SNPs that failed Hardy-Weinberg equilibrium with P<10 −7 were excluded.
In EPIC-Norfolk, various laboratory measurements, including a conventional lipid profile, were performed at baseline as previously described. 9 When additional funding became available in 2010, additional measurements were performed in a subset of the cohort with available stored frozen blood samples. Lipoprotein(a) levels were measured with an immunoturbidimetric assay using polyclonal antibodies directed against epitopes in apolipoprotein(a) (Denka Seiken, Coventry, United Kingdom) as previously described. 12 This assay has been shown to be apolipoprotein(a) isoform-independent.
Statistical Analyses
For the prospective analysis in the EPIC-Norfolk cohort, study participants were excluded if lipoprotein(a) levels were missing. Baseline characteristics of study participants were compared between participants who developed AVS during follow-up versus those who did not using an unpaired Student t test for continuous variables with a normal distribution, a Mann-Whitney U test for continuous variables with a non-normal distribution, or a χ 2 test for categorical variables. Cox regression analysis was used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) for the time to hospitalization or death because of AVS. Lipoprotein(a) levels or rs10455872 genotype categories were used as independent variables. Regression models were tested before and after adjustment for potential confounding risk factors. An instrumental analysis was conducted to assess the per-allele increase of age-and sex-adjusted genetically elevated lipoprotein(a) levels using the following formula: lipoprotein(a)=c+β 1 (age)+β 2 (sex)+β 3 (LPA genotype), as previously described. 7 We used the additive model to test the association between genetic variants in the IGF2R-SLC22A1-A2-A3-LPAL2-LPA-PLG region with a minor allele frequency ≥5% and AVS risk using logistic regression after adjusting for age and sex in the MHI Biobank. In EPIC-Norfolk, statistical analyses were performed using SPSS software version 20, and PLINK was used for genetic association studies in the MHI Biobank.
Results
Lipoprotein(a) Levels and AVS Risk in the EPIC-Norfolk Study
In EPIC-Norfolk, lipoprotein(a) levels were available in 17 553 study participants. Among these, 118 were identified with incident AVS during follow-up through March 31, 2010.
Baseline characteristics of the study participants are shown in Table 1 for cases and controls separately. Of note, 250 study participants (1.4%) were on lipid-lowering therapy.
The association between lipoprotein(a) levels and risk of incident AVS is shown in Table 2 . Compared with participants in the bottom lipoprotein(a) tertile, study participants in the top lipoprotein(a) tertile were at increased AVS risk (unadjusted HR, 1.66; 95% CI, 1.08-2.56, versus HR, 1.57; 95% CI, 1.02-2.42 when adjusting for age, sex, and smoking). Further adjustment for low-density lipoprotein cholesterol levels had a minor impact on the relationship between lipoprotein(a) levels and AVS risk. Given that the European Society of Cardiology guidelines have suggested that a desirable level of lipoprotein(a) was <50 mg/dL, we assessed the relationship between AVS event rates in patients with lipoprotein(a) levels <50 versus ≥50 mg/dL. Our results suggest that even after adjusting for age, sex, smoking, and low-density lipoprotein cholesterol levels, patients with lipoprotein(a) levels ≥50 mg/ dL are at significantly increased AVS risk ( Table 2) .
LPA Genetics, Lipoprotein(a) Levels, and AVS Risk in the EPIC-Norfolk Study
The rs10455872 genetic variant was genotyped in 14 735 study participants in whom lipoprotein(a) levels were also available. Table 3 shows the association between lipoprotein(a)-raising alleles and lipoprotein(a) levels, as well as with AVS risk using either an additive model or a dominant model, before and after adjusting for lipoprotein(a) levels, log-transformed lipoprotein(a) levels, and lipoprotein(a) quintiles. There was a positive association between the number of lipoprotein(a)raising alleles and lipoprotein(a) levels. There was also a strong and positive association between rs10455872 and AVS risk, which was only slightly affected after further adjustment for lipoprotein(a) levels, log-transformed lipoprotein(a) levels, or lipoprotein(a) quintiles.
To further address the potential causality of this genetic variant, we performed an instrumental variable analysis, whereby the increment of lipoprotein(a) levels per rs10455872 G allele was tested for its association with AVS. Linear regression yielded a sex-and age-adjusted per-allele increment of 31.1 mg/dL of plasma lipoprotein(a) as shown in Figure 1 . The HR for AVS risk was 1.95 (95% CI, 1.34-1.60) per each additional rs10455872 G allele, whereas the HR for AVS risk per 31.1 mg/dL lipoprotein(a) increment was considerably lower (HR, 1.31; 95% CI, 1.07-1.60).
LPA Locus and AVS Risk in the MHI Biobank
The clinical and echocardiographic characteristics of the MHI Biobank are shown in Tables I and II in the Data Supplement, respectively. The rs10455872 genetic variant along with 583 other SNPs in the IGF2R-SLC22A1-A2-A3-LPAL2-LPA-PLG region with minor allele frequencies ≥5% were genotyped in this cohort. The association between all SNPs in this region and AVS risk is shown in Figure 2 . These results confirm that the rs10455872 variant is indeed positively associated with AVS risk. However, several other variants located upstream of the rs10455872 variant could also be predictive of AVS risk. Table 4 shows the results of the genetic association test for rs10455872 and for other SNPs in this region that were associated with AVS risk with a P value <1×10 −3 .
Discussion
Results of the present study show that individuals with high lipoprotein(a) levels are at increased risk of AVS. To the best of our knowledge, this study is the first with a longitudinal design to suggest that lipoprotein(a) levels are a strong risk factor for AVS. Because reverse causality cannot be fully addressed in this study design, we have genotyped a common variant in the LPA region (rs10455872) that is closely associated with lipoprotein(a) levels. Our results also show that the number of rs10455872 G allele associated with elevated lipoprotein(a) levels is strongly associated with AVS risk, which suggests that the relationship between lipoprotein(a) and AVS is likely to be causal. In addition, several other variants located upstream of the LPA gene were also shown to be associated with AVS risk.
With the exception of the recent report of CHARGE Consortium, 7 literature on lipoprotein(a) levels and AVS risk is scarce. The association between lipoprotein(a) levels and presence of aortic valve sclerosis and stenosis was first demonstrated in a cross-sectional analysis of the Cardiovascular Health Study. 5 A previous case-control study has suggested that lipoprotein(a) levels may be elevated in patients with AVS, 8 and 1 other study observed that patients with aortic valve calcification had significantly higher lipoprotein(a) levels compared with patients without aortic valve calcification. 13 Also, despite an early finding suggesting that hyperlipidemic transgenic rabbits expressing the human apolipoprotein(a) gene have increased vascular calcification, studies that have sought to establish a link between lipoprotein(a) levels and coronary calcification in humans have yielded conflicting results. [14] [15] [16] Considerable evidence supports a role for lipoprotein(a) in the pathophysiology of AVS. First, lipoprotein(a) is a risk factor for cardiovascular disease (CVD), and AVS shares several common risk factors with CVD. Second, at the cellular level, lipoprotein(a) and isolated apolipoprotein(a) have been shown to trigger smooth muscle cell proliferation via the activation of transforming growth factor β. 17 Given that there is now compelling evidence for a role of transforming growth factor β signaling in the pathophysiology of AVS (as recently reviewed by Xu et al 18 ), lipoprotein(a) could induce valvular calcification via the transforming growth factor β pathway, although experimental studies are required to confirm this association. Lipoprotein(a) has also been shown to activate macrophages and increase interleukin-8 secretion in vitro. 19 In addition, oxidized, but not native, low-density lipoprotein particles could activate macrophages and promote valvular calcification in humans. 20 Because lipoprotein(a) can act as an important carrier of oxidized phospholipids, which have been identified as significant predictors of the onset of CVD in a nested casecontrol data set of the EPIC-Norfolk study, lipoprotein(a) may promote calcification via its pro-oxidant properties.
It has been suggested that >90% of the variance in serum lipoprotein(a) concentrations is explained by variations in and around the LPA locus on chromosome 6q27, which makes lipoprotein(a) an ideal candidate for Mendelian randomization studies. 21 The purpose of an analysis of this kind is to test whether lifelong exposure to a biomarker, such as elevated lipoprotein(a) levels in our case, would increase AVS risk independently of potential confounders by other phenotypes or clinical characteristics that could influence serum lipoprotein(a) levels. We have chosen to study rs10455872 for 3 reasons: (1) It is the common variant that has shown the strongest association with lipoprotein(a) levels in genomewide association studies. 22 (2) This genetic variant is frequently used as a proxy of Kringle-IV type 2 repeats in the LPA gene. 23 (3) It was the SNP with the strongest association with aortic valvular calcium in a recent genome-wide association study. 7 Additionally, several other genetic variants located upstream of the LPA locus were identified as being associated with aortic valvular calcification in this genome-wide association study. Interestingly, we also found that several genetic variants located upstream of the LPA locus were associated more strongly with AVS compared with rs10455872. Although these were not in linkage disequilibrium with rs10455872, they could nevertheless be associated with different apolipoprotein(a) isoforms, apolipoprotein(a) mRNA expression, and lipoprotein(a) levels. 22 Although neither statins nor fibric acid derivatives influence lipoprotein(a) levels, several other lipid-lowering therapies have been shown to lower plasma lipoprotein(a) levels to varying extent. These include proprotein convertase subtilisin/kexin type 9 inhibitors, 24 antisense oligonucleotides targeting apolipoprotein B mRNA, 25 thyroid hormone analogs, 26 and niacin. 27 A recent report from the European Atherosclerosis Society consensus panel suggested screening for lipoprotein(a) levels in patients at intermediate or high CVD risk. 28 The panel also suggested the use of niacin for CVD risk reduction in patients with plasma lipoprotein(a) levels above the 80th percentile. This recommendation, together with the findings of the current study, raises the question of whether or not niacin (or any other lipoprotein(a)-lowering agent) could be beneficial for the prevention of AVS or the improvement of aortic valve function in patients with AVS and high lipoprotein(a) levels. Because the association between the rs10455872 variant and AVS risk was partly independent of plasma lipoprotein(a) levels and because genetic alleles associated with high elevated lipoprotein(a) were more strongly associated with AVS risk compared with a similar increment of actual plasma lipoprotein(a) levels, it is possible that the association between this genetic variant and AVS risk may be mediated through mechanisms other than the difference in plasma lipoprotein(a) levels. Whether this is because of the lower number of Kringle-IV type 2 repeats per apolipoprotein(a) associated with this variant or another segregating phenotype is unknown. This finding also questions whether all individuals with high lipoprotein(a) or only those with genetic profiles associated with elevated lipoprotein(a) should be targeted with lipoprotein(a)-lowering agents for the prevention or regression of AVS. It should also be considered that this aspect contrasts with the results reported by the Precocious Coronary Artery Disease (PROCARDIS) consortium that investigated the association between 2 genetic variants associated with lipoprotein(a) levels (including rs10455872) and CVD risk. 23 In that study, adjustment for lipoprotein(a) levels completely eliminated the relationship between the genotype score and CVD risk. Another potential explanation for the stronger association between genetic profiles associated with elevated lipoprotein(a) compared with plasma-measured lipoprotein(a) levels with AVS risk is the fact that these may represent lifelong exposures and are less susceptible to random measurement error, as opposed to a single plasma lipoprotein(a) concentration measured on one occasion. Several aspects of the study design need to be taken into account when interpreting the results of the present study. The longitudinal design of this study is a major advantage to follow the natural occurrence of AVS in an apparently healthy population, because it avoids the inherent biases associated with cross-sectional study designs. However, despite the fact that our cohort was large, the low incidence of AVS in general population samples still resulted in relatively few events. In addition, given the fact that we used AVS-related hospitalizations and mortality as outcome, this outcome definition is likely to be restricted to the most severe and symptomatic cases, rather than including just the mild and asymptomatic ones. Another limitation is the fact that in EPIC-Norfolk the AVS study outcome was based on International Classification of Diseases, 10th Revision-coded hospitalizations and mortality, and not validated against echocardiography reports. In addition, AVS diagnosis was indeed confirmed by echocardiography in the MHI replication study, which included a sufficient number of cases.
In conclusion, the results of the present study suggest that patients with high lipoprotein(a) levels are at increased risk for AVS. The fact that a common genetic variant in LPA is simultaneously associated with both serum lipoprotein(a) levels and risk of AVS further suggests that this association is likely to be causal. Our report also shows that several other genetic variants in the expanded LPA region could also be associated with AVS. Whether pharmacological interventions that influence lipoprotein(a) levels will reduce the risk of AVS in patients with high lipoprotein(a) levels should be tested in randomized clinical trials.
